Company news

4D Molecular Therapeutics, Inc. news in 2026

4D Molecular Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

4DMT to Participate in Upcoming Investor Conferences

November 3, 2026

4DMT Announces New Employment Inducement Grants

October 16, 2026

4DMT to Host Investor Day on October 21, 2026

October 5, 2026

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

September 28, 2026

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

August 13, 2026

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

July 18, 2026

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

June 30, 2026

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

June 29, 2026

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

June 29, 2026

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 7, 2026

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

March 17, 2026

4DMT to Participate in Upcoming Investor Meetings

March 16, 2026

4DMT Announces New Employment Inducement Grants

February 13, 2026

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

February 9, 2026

4DMT Provides Company Update and Anticipated Development Milestones for 2026

January 7, 2026

Decks in 2026